This dual action—attenuating MyD88-dependent cytokine storms and stabilizing vascular integrity—aligns with ischemic stroke pathophysiology, particularly in subacute phases where controlled Tlr2 inhibition may balance inflammatory resolution and angiogenesis. Here, MYD88 is linked to ischemic stroke.